Clinical efficacy of modified two-stage hepatectomy combined with immunotherapy plus tar-geted therapy in the treatment of borderline resectable liver cancer
10.3760/cma.j.cn115610-20240606-00278
- VernacularTitle:改良二步肝切除联合免疫靶向治疗临界可切除肝癌的临床疗效
- Author:
Peng YAO
1
;
Jiasui CHAI
;
Deng PAN
;
Yan CHEN
;
Xu WANG
;
Hongjie ZHANG
;
Xiaozheng LI
Author Information
1. 山西医科大学附属运城市中心医院肝胆外科，运城 044000
- Keywords:
Liver neoplasms;
Associating liver partition and portal vein ligation for staged hepatectomy;
Conversion therapy;
Hepatectomy;
Multidisciplinary
- From:
Chinese Journal of Digestive Surgery
2024;23(7):984-988
- CountryChina
- Language:Chinese
-
Abstract:
Hepatectomy is the most effective method for the treatment of liver cancer. Asso-ciating liver partition and portal vein ligation for staged hepatectomy (ALPPS) provides resectable opportunities for patients with unresectable or borderline resectable liver cancer. Traditional ALPPS procedures involve a short interval between two stages of the surgery, leading to a higher incidence of perioperative complications and mortality. The authors present a case of two-stage hepatectomy. Initially, laparoscopic ligation of the right hepatic artery and portal vein was performed. To prevent tumor progression after the first stage of surgery, combined immunotherapy and targeted therapy were administered. Three months later, a successful right hemihepatectomy was performed. Postoperative histopathological examination revealed hepatocellular carcinoma with extensive tumor necrosis. A 15-month follow-up showed no tumor recurrence. This indicated that two-stage hepatectomy including simultaneous ligation of the hepatic artery and portal vein, combined with two-stage hepatectomy plus immunotherapy and targeted therapy, showed considerable promise for borderline resectable liver cancer.
